

## Laprituximab

|           |   |
|-----------|---|
| Cat. No.: | HY-P99684   |
| CAS No.:  | 1622327-38-1  |
| Target:   | EGFR  |
| Pathway:  | JAK/STAT Signaling; Protein Tyrosine Kinase/RTK   |
| Storage:  | Please store the product under the recommended conditions in the Certificate of Analysis. |

### BIOLOGICAL ACTIVITY

|             |  |
|-------------|--|
| Description | Laprituximab (J2898A) is a humanized IgG1 anti-EGFR antibody that can be used for the synthesis of ADC IMGN289 <sup>[1]</sup> .  |
| In Vivo     | In the H292 xenograft tumor model, the minimally effective doses of Laprituximab (J2898A) is 3 mg/kg <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

### REFERENCES

[1]. Chittenden T D, et al. IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway. Cancer Research, 2013, 73(8\_Supplement): 5467-5467.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA